Carteolol
From Wikipedia, the free encyclopedia
| Image:Carteolol.png | |
|
Carteolol
|
|
| Systematic (IUPAC) name | |
| 5-[2-hydroxy-3- (tert-butylamino) propoxy]- 3,4-dihydro-1H-quinolin-2-one | |
| Identifiers | |
| CAS number | 51781-06-7 |
| ATC code | C07AA15 S01ED05 |
| PubChem | 2583 |
| DrugBank | APRD00195 |
| Chemical data | |
| Formula | C16H24N2O3 |
| Mol. weight | 292.373 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Carteolol is a beta blocking agent
[edit] External links
- El-Kamel A, Al-Dosari H, Al-Jenoobi F. "Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride.". Drug Deliv 13 (1): 55-9. PMID 16401594.
- Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A (2005). "Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro.". Cornea 24 (2): 213-20. PMID 15725891.
- Trinquand C, Romanet J, Nordmann J, Allaire C (2003). "[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]". J Fr Ophtalmol 26 (2): 131-6. PMID 12660585.
| Antiglaucoma preparations and miotics (S01E) edit | ||
|---|---|---|
| Sympathomimetics: |
Apraclonidine, Brimonidine, Clonidine, Dipivefrine, Epinephrine |
|
| Parasympathomimetics: |
Aceclidine, Acetylcholine, Carbachol, Demecarium, Echothiophate, Fluostigmine, Neostigmine, Paraoxon, Physostigmine, Pilocarpine |
|
| Carbonic anhydrase inhibitors: |
Acetazolamide, Brinzolamide, Diclofenamide, Dorzolamide, Methazolamide |
|
| Beta blocking agents: |
Befunolol, Betaxolol, Carteolol, Levobunolol, Metipranolol, Timolol |
|
| Prostaglandin analogues: |
Bimatoprost, Latanoprost, Travoprost, Unoprostone |
|
| Other agents: |
Dapiprazole, Guanethidine |
|
